Buprenorphine is typically detectable in a urine test for up to 7 days after your last dose. That window can be shorter, closer to 2 to 4 days, depending on whether you took a single dose or have been using it regularly. Several factors shift this timeline, including the form of buprenorphine you’re taking, how long you’ve been on it, and the sensitivity of the test being used.
Detection Window by Usage Pattern
If you’ve taken buprenorphine once or only a few times, it will generally clear your urine faster than if you’ve been on a maintenance regimen. For occasional or short-term use, both buprenorphine and its primary breakdown product (norbuprenorphine) are detectable for roughly 2 to 4 days. For people taking it chronically, as part of an opioid use disorder treatment program, that window extends and can reach up to 7 days after the last dose.
The reason for the difference is accumulation. When you take buprenorphine daily over weeks or months, the drug and its metabolites build up in your body’s tissues. After you stop, it takes longer for those stored reserves to be fully processed and eliminated. Your body doesn’t excrete much of the parent drug itself through urine. Instead, the liver breaks buprenorphine down into norbuprenorphine and other metabolites, and those are what urine tests primarily detect.
Injectable Buprenorphine Is a Different Story
If you’ve received an extended-release injection (sold under the brand name Sublocade), the detection window is dramatically longer. This formulation deposits a solid mass of buprenorphine under the skin that slowly releases the drug over weeks. After discontinuing the injection, buprenorphine can remain detectable in urine for 12 months or longer. This is important to know if you’re transitioning off treatment or expecting a drug screen, because the timeline has nothing to do with recent use. It reflects the slow, steady release from the injection site.
What the Test Actually Measures
Standard urine tests for buprenorphine don’t rely on the same immunoassay panels used to screen for common opioids like morphine or oxycodone. Buprenorphine requires its own specific test. A routine workplace drug screen won’t detect it unless buprenorphine has been explicitly added to the panel.
The most precise method uses a technology called liquid chromatography-tandem mass spectrometry. According to Mayo Clinic Laboratories, this test flags a result as positive when buprenorphine is above 5.0 ng/mL or norbuprenorphine is above 2.5 ng/mL. Both substances share an approximate detection window of up to 7 days, though the actual time depends on dose, frequency of use, and individual metabolism.
Less precise immunoassay screens do exist for buprenorphine, and they can occasionally produce false positives. A small number of medications are known to cause cross-reactivity on these screens, including tramadol and two antipsychotic drugs (amisulpride and sulpride). If you test positive on an initial screen but haven’t taken buprenorphine, a confirmation test using the more precise method can rule out a false result.
Factors That Affect Your Timeline
The 2-to-7-day range is a general guide, not a guarantee. Several individual factors push the detection window shorter or longer:
- Dose size: Higher doses produce more metabolites that take longer to clear. Someone on 24 mg daily will test positive longer than someone on 2 mg.
- Duration of use: Months or years of daily use means greater tissue accumulation and a slower elimination curve compared to a few days of use.
- Metabolism: Your liver processes buprenorphine through a specific enzyme pathway. People with faster metabolisms or healthier liver function will clear it more quickly. Liver disease or impairment slows elimination.
- Body composition: Buprenorphine is fat-soluble, so it can be stored in fatty tissue. People with higher body fat percentages may retain detectable levels slightly longer.
- Hydration and urine concentration: A very dilute urine sample may fall below the test’s cutoff threshold sooner, while concentrated urine may test positive for a longer window. This doesn’t change how fast your body eliminates the drug, just whether a given sample crosses the detection line.
Sublingual vs. Other Formulations
The form you take also matters because it affects how much buprenorphine actually enters your bloodstream. Sublingual tablets and films (placed under the tongue) deliver roughly 13 to 14% of the dose into your system, with the rest broken down before it reaches circulation. This means a higher proportion of metabolites ends up in urine compared to the parent drug. In fact, research on urinary excretion has found that no free buprenorphine (the unchanged parent drug) appears in urine at all. What the test picks up is entirely the metabolized forms.
Combination products that include naloxone (like Suboxone) don’t meaningfully change the buprenorphine detection window. Naloxone has a much shorter duration in the body and is tested for separately when monitoring is needed. Its presence in the formulation doesn’t speed up or slow down how long buprenorphine metabolites remain in your urine.
How This Compares to Other Opioids
Buprenorphine sticks around longer than most short-acting opioids. Drugs like oxycodone, hydrocodone, and morphine are typically detectable in urine for 2 to 4 days. Buprenorphine’s longer window reflects its unusually strong binding to opioid receptors and its slow release from those binding sites. Methadone, another long-acting opioid used in treatment programs, has a comparable detection window of roughly 3 to 7 days, though it too varies with chronic use.
If you’re being tested as part of a treatment compliance program, the goal is usually to confirm you are taking your buprenorphine, not to catch you using it. Providers look for appropriate levels of both buprenorphine and norbuprenorphine to verify the medication is being taken as prescribed rather than diverted. An absence of norbuprenorphine alongside high buprenorphine levels, for example, could suggest the drug was added to the sample rather than actually taken, since the body always produces norbuprenorphine when processing a real dose.